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1 Introduction
Drug design is a process of developing new marketable drugs for the treatment
of diseases humans are plagued with. Usually it starts by identifying the target,
be it a receptor, enzyme, ion channel, DNA or something else, which a drug is
supposed to activate, inhibit or regulate in order to achieve a desired medicinal
effect. Target found, begins a search for a lead compound, a molecule that in
assay tests exerts activity towards the target, but is not suitable for a drug due
to any number of reasons, such as excessive toxicity, poor selectivity and, most
likely, low activity. However, lead compound can be tweaked to give it a desired
pharmacokinetic profile and enhance its potency. This process ends up with a
drug candidate, a compound that exhibits the desired properties of the drug and is
therefore subjected to thorough biological and pharmacological testing. Final step
in drug design process is clinical drug, a drug candidate that has passed all the
required conditions regarding toxicity, metabolism, side effects etc., and is ready
for clinical trials.1,2 The process is often iterative, with several steps of redesign
and retesting, as exemplified on some existing drugs.3
Drug design is expensive and time consuming, therefore not surprisingly, op-
tions of transferring it into computers as extensively as possible are intensively
investigated. There is no way to avoid the clinical trials in foreseeable future,4
however, it is a different story for less stringent steps of drug development such as
the lead discovery. This part has always heavily relied on random screening and
in cases where there is no knowledge about the target, or no known natural lead
compound is known, it is essentially the only option.2 Today this takes a form of
high throughput screening (HTS) – hundreds of parallel experiments conducted
simultaneously in robotised manner. Since HTS is intended for scanning millions
of compounds, of which only a tiny fraction are even remotely active, it is often
compared to finding a needle in a haystack. The idea then is not to accurately
measure several million activities, but rather to find a few interesting compounds
to continue with. This is feasible for computational methods and therefore lead
and drug candidate discovery have on numerous occasions been successfully com-
plemented with or even replaced by in silico methods collectively known as virtual
screening (VS). For that reason VS is often seen simply as an in silico analogue of
HTS, and while it can be seen in section 2.3, that its ambition goes a bit further
than that, they do work and gain results in a rather similar manner. Like HTS,
VS does not deliver a finished product. Instead, the objective is to concentrate
the data set in terms of interesting compounds for further development, eliminate
those that are obviously unsuitable or just pick out a handful of most prospective
ones.5
This thesis presents a research on the topic of virtual screening. Overview of the
current state, problems, perspectives as well as most important methods is given
in chapter 2. Chapter 2.3 summarises the methodology used in the study, and the
results of the original research are presented in chapter 4.
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2 Literature overview
2.1 Methods of virtual screening
While the objective of all the VS methods is the same, means of achieving it
can be considerably different. For that reason it is often observed, that different
methods may have considerably different behaviour. Some methods can work better
on some systems, they can be complementary, or even select completely different
compounds. Understanding of the methods quirks can therefore be insightful when
choosing the one to use.
The most important means of classification is distinguishing between ligand-
and structure-based methods. Structure-based virtual screening (SBVS) requires a
receptor structure to be known beforehand, derived either form from X-ray diffrac-
tion, nuclear magnetic resonance or homology modelling. This structure is then
used to describe ligand-receptor interactions that are necessary for good binding.
Ligand-based virtual screening (LBVS) does not require a target structure, only
one or several known ligands are needed and the new ones are found based on
similarities to the old ones.
The second important difference is based on the structural information methods
rely on, namely 2D and 3D methods. 2D refers to the structure of molecular
graph, atom connectivity and whatever information can be derived from this. 3D
is the molecule’s spatial structure, atomic coordinates in space. The dimensionality
axis can be elongated in both directions, there are 1D methods, that require only
molecular composition, and 4D methods which also consider molecule’s flexibility;
but the difference between 2D and 3D is the most significant, and these two are
the most common in VS.
Due to plethora of methods, their unique classification is rather hopeless and
various authors have used different schemes in their papers. For that reason, the
following list does not follow any particular classification scheme, it is a selection
of most important VS methods by the names used commonly in literature.
2.1.1 Molecular docking
The method that most closely resembles an actual experiment, to the extent that
it can be called virtual experiment, is molecular docking. The ligand molecule is
quite literally placed into the binding site of the target and their affinity towards
each other is evaluated. Its straightforward approach to the problem attributes
to its popularity – a recent study by Ripphausen et al.6 where almost 500 papers
were examined, shows that docking is the single most popular VS method out there.
Combined with the fact that it has been around for a while,7,8 it has become almost
a synonyme of virtual screening.
While the general idea is intuitive and easily graspable, internals of the process
are dauntingly complicated. It can be seen as a two step process, whereas the
first step includes finding a correct pose for the ligand and placing it into the
binding site. While earliest adaptations of docking techniques treated both ligand
and protein as rigid bodies, today most docking programs employ flexible ligand-
rigid receptor paradigm; and with the increasingly powerful computer hardware,
combined with the emerging understanding of importance of protein flexibility9–11,
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fully flexible systems are emerging. Ligand flexibility can be accounted through
pre-generated conformational ensemble or in-place conformational sampling. For
protein flexibility, there are more options: soft docking, which allows simply some
overlap of van der Waals radii in ligand and protein atoms; side chain flexibility,
where protein backbone is kept fixed whereas side chains are allowed to move;
molecular relaxation, which allows also some backbone flexibility; and, similarly to
ligand flexibility modelling, an ensemble of protein structures.12
After the ligand is fitted, its affinity towards protein is evaluated through some
scoring function. They fall into three classes: force-field-based, empirical, and
knowledge-based.12,13 The former takes advantage of some existing force field and
uses its parameters to evaluate individual interaction terms such as van der Waals
energies, electrostatic energies, bond stretching/bending/torsional energies, etc.
separately. It is simple and straightforward, but its problem areas are accounting
for entropic and solvent effects.12 Empirical and knowledge-based scoring functions
derive their predictive capacity from a set of known protein-ligand interactions,
but handle the data in training set a bit differently. Empirical scoring functions
evaluate binding energy by summing the contributions of individual components,
commonly hydrogen bonds, entropic terms, ionic, and hydrophobic interactions.
These are evaluated as a geometric function of ligand and receptor coordinates
which are derived form empirical data using least-square fitting. They are more
efficient to calculate, but depend heavily on the quality of training set. Knowledge-
based scoring functions make their decision by summing all the interaction terms of
all protein-ligand atom pairs, which are derived from the frequency that a particular
distance is observed in a database. It is based on the concept of potential mean
force, defined by inverse Boltzmann relation.14,15 The large number of complexes
used for training is expected to bias the values towards the existence of specific
contacts and absence of repulsive interactions. Knowledge-based functions are a
good compromise between force-field based and empiric scoring functions in terms
of both computational efficiency and accuracy, while being relatively robust and
general.16–18
One use for docking is the calculation of the binding affinities between lig-
and and receptor. There is a number of docking programs available, such as
Autodock19, FlexX20, Gold21, Glide22,23, DOCK24, to name just a few of the
most popular ones. Different programs, employing different geometry handling
procedures and different scoring functions give different results, which is not all
that surprising. However, no single program regrettably performs consistently bet-
ter than the others. Studies comparing different programs have pointed out that
certain programs work better on certain target classes or active site types, but
not uniformly across target space.25–29 Some limited success has been noted on
homogeneous series,30 but otherwise it has to be concluded that to date, binding
affinity prediction remains the toughest assignment of the docking, despite intense
studies.31–33 In fact, the correlation between experimental and calculated affinities
is so short of perfect, docking programs lack even the capacity to correctly rank
the molecules. Results of docking studies are therefore often evaluated using en-
richment34 – number of active ligands in top x% of the top-scoring compounds.
Docking is also used to find a ligand’s binding mode, and when applied to this prob-
lem, the results are much better. The same studies quoted earlier, that concluded
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poor performance on binding energies, report greater success on pose prediction
and finding natural binding poses, to the extent that on certain cases, a single best
performing program could be pointed out.29
The difficulties with affinity predictions stem from the condensed phases in
which biology occurs, and the many degrees of freedom of biomolecules.35 All
contributing factors, such as structure of the host, ionization states, structure of
the complex, internal degrees of freedom, solvation states, and the host-ligand
energetics, are potential error sources. As Tirado-Rives and Jorgensen pointed
out, there is only a small activity window for a good hit; it is highly unlikely to
find a library compound with the activity above ~50 nM, and below 100 µM there
are too many difficulties with experimental determination and lead optimisation to
consider the molecule further. That difference corresponds to free energy difference
of 4.5 kcal/mol and the free energy contributions from conformational factors alone
for typical drug-like ligands (which are usually neglected in most scoring functions)
can be as large as this.36 The authors conclude that predicting affinities reliably
for large and diverse molecular libraries, is currently beyond reach.
Despite of the current shortcomings, docking is, as mentioned earlier, the most
popular VS method and it holds the greatest potential for the future. It is ac-
tively developed,33,37 and has publicly available libraries ready for docking such
as the ZINC database38; and validation, such as the Directory of useful decoys
(DUD).39,40
2.1.2 Fingerprints and similarity search
While docking is clearly a structure-based method, similarity search in majority of
cases refers to ligand-based approach. The idea is to describe a molecule using a
collection of parameters and search for new ligands with similar values. The result
then depends on both how the molecules are characterised and how the conformity
of parameters is assessed.
A fingerprint is in essence a vector, in a simplest case a binary vector where
each bit corresponds to a predefined structural feature which is searched from the
molecule and marked down as 1 if found and 0 if not. This representation is quite
intuitive and even human-readable, although to carry a meaningful amount of in-
formation, structural key libraries must be rather large, which has a negative effect
on extraction time and comparison efficiency. Additionally, they would contain
mostly zeroes, because in order to be representative, a library must encompass a
large number of structural features and one cannot possibly expect to find them
all in a single drug-like molecule.
There are two solutions to the sparse vector problem, one is to use some com-
pressing technique or hashing function which loses negligible amount of informa-
tion, but results with shorter and denser fingerprint. Another is to extract infor-
mation directly from the molecule itself, to describe each atom, its environment,
connectivity to neighbours and paths connecting to other atoms. Since this type
of information depends on the molecule’s size, doing it in a manner where each
individual bit in the fingerprint corresponds to a certain feature, would result in
fingerprints of variable length, a problem when the aim is to compare them. In-
stead, the fingerprint is set to a fixed length and the information is added using
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logical “OR” operation. The advantages over predefined libraries include (besides
not having to compose one), faster extraction times and avoiding the problem of
poorly constructed library.
Once the fingerprints are composed, they can be compared using certain co-
efficients. It is not an unique problem, several disciplines require such compar-
isons, therefore numerous similarity indices have been developed.41 Some of them
are strongly correlated or monotonous (ordering the molecules in the same way),
others again entirely unrelated, suggesting that they capture completely different
aspects of the object.41,42 A similarity coefficient can directly measure similarity
between two compounds, like Tanimoto or Cosine index or dissimilarity, distance
in chemical space like Euclidean or Hamming distance. Some of them see a com-
mon absence of a feature a similarity, others do not. Tanimoto index, for example,
does not, therefore it could be slightly size-biased, making small molecules, that
have less bits set in their fingerprints, appear less similar.43 Despite that it has
become a de facto standard in measuring similarity of compounds. Most common
similarity measures in chemoinformatics have been discussed by Willett et al.43
Since fingerprints are simple mathematical constructs, their usage in chemoin-
formatics as a molecular descriptor is rather universal. Fingerprints described here
so far are extracted from the 2D molecular graphs, but really anything can be
encoded using the same principle, including 3D structures,44 protein-ligand com-
plexes,45–47 and even spatial shapes of molecules.48 Due to a wide range of appli-
cation, they are often used and found to be advantageous in many ways. Their
calculation, storage and comparison is computationally efficient, they are based on
simple concepts, but despite that, they are often found to be comparably effec-
tive to much more elaborate methods.49 Compared to docking, which attempts to
model the exact physical interaction between the ligand and receptor, similarity
search using fingerprints, might seem a bit sketchy and unreliable, without real
physical background. This is exactly the way as it was seen earlier – in 1998 Willet
et al. comment on the similarity search as “a very crude way of accessing a struc-
tural database” and suggest that when there is more than one molecule available,
other LBVS methods should be applied and ultimately, when receptor structure
is available, SBVS should be used.43 Since then, the attitude has changed consid-
erably,50,51 and as of today, it is an established VS method with many success
stories.6,52
2.1.3 Pharmacophores
A pharmacophore describes the portion of the ligand that is responsible for trig-
gering the desired biological response during interaction with the macromolecule.
It is not an exact description of the ligand, it is rather a common denominator of
several ligands that follow the same binding mode. Functional groups contributing
into binding, usually hydrophobic, aromatic, charges, hydrogen bond donors and
acceptors, are identified and described as points in three-dimensional space. This
pattern of groups can then be used to find new ligands, based on the placement of
the same type of functional groups in the molecule, and distances between them.
This is indeed the most straightforward usage of the pharmacophore, but being
such an abstract and universal concept it is, similarly to fingerprints, embedded
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deeply into virtual screening, and can be encountered in many different methods.53
This flexibility is what makes pharmacophores such a powerful approach. It can
be used as both ligand-based and structure-based method, meaning that pharma-
cophoric pattern can be extracted from active ligands or receptor structure.54 It can
manage the flexibility of ligands and proteins through series of conformations.55
When activity values of ligands are added to the equation, the most favourable
groups can be identified. When derived from the receptor structure, the shape
of the binding site can be taken into account by defining forbidden areas for the
ligand, effectively avoiding clashes with the receptor.56 Since only the groups re-
sponsible for the interaction are defined and no assumption is made about the
molecule between them, finding novel scaffolds is easily achievable, both in the-
ory and practice.57 All that considered, it is not surprising that pharmacophores
have many success stories. Due being faster than docking, it is often used as a
pre-screening tool, although studies have demonstrated its comparable efficiency.
Pharmacophores are usually depicted separately from similarity search, but the
information extracted in this way can easily be encoded into fingerprint notation
and used as such.44,53,58
2.1.4 Shape similarity
Considering the close complementarity of receptor and a bound ligand, observ-
able in an X-ray structure, the importance of molecular shape is deeply rooted in
medicinal chemistry.59 The “lock-and-key” metaphor for ligand-receptor binding
allows to raise an hypothesis that active ligands should have similar shape and
volume. This concept is exploited in shape matching techniques, which attempt to
find molecules with similar volumetric arrangement in three-dimensional space.
The first task in the process is to describe the shape in some mathematically
approachable way. Popular methods have been described by Putta and Beroza
in their excellent review.48 To summarise, they fall into four categories: moment-
based, gnomic-based, volume-based, and surface-based methods. Moment-based
methods describe the molecule as the set of multipole moments of inertia;60,61
they are efficient to calculate and are often used as preliminary alignment. Gnomic
methods map the molecule onto a simple surface and the points of that surface are
encoded with additional information, such as distance to closest pharmacophoric
groups.62,63 Volume-based shape representation is currently most common, it is
used in leading shape matching programs, ROCS64,65 and SW/SQW66. Atoms in
molecule are described as intersecting hard spheres with van der Waals radius,67 or
Gaussian functions.68 The latter is advantageous due to more efficient calculation
and simplified mathematical operations. Steric grid can also be used in volume-
based representations; each grid point receives a value describing its relation to
underlying molecular shape. Probably the most accurate approach in shape de-
scription is the surface-based representation. The surface can be described as a
shell of finite width69 or set of patches on the surface of the molecule’s shape.70,71
This is less common due to complicated calculations.
The shape alone is not enough to determine if a ligand binds to a macro-
molecule. Interactions such as hydrogen bonding, ionic, hydrophobic, and van der
Waals forces among others, also have an important role,72 therefore shape similar-
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ity methods also look for an additional information in the molecules. Depending
on the method used for shape description, this information can be encoded as
atom types,66,73,74 coloured grid points75 or surface points.62,76 Interestingly, too
detailed description may not be the best solution, the findings of Sastry et al. sug-
gest that simple pharmacophoric colouring is preferable to exact atom mapping.77
Similarly to pharmacophores, shape derived from the molecule can be used
directly to search for matches with other molecules, but it is also possible to encode
it in the form of molecular descriptors, such as fingerprints.78,79 Following a similar
derivation route, 3D shape fingerprints are composed from a library of predefined
shapes. Once prepared, they can be used as conventional fingerprints, described
in section 2.1.2. Same approach of comparison applies also to a method described
by Zauhar et al., where a histogram is composed from the lengths of rays reflected
inside the surface of the molecule.80
The strength of the descriptor-based approach is that it avoids the most chal-
lenging aspect of shape matching – the alignment of structures. Alignment at-
tempts to find one or more three-dimensional overlays of one molecule onto the
other. This problem can be solved in numerable ways and the details of individual
programs vary, but a distinction of global and local shape alignment can be made
– global methods seek to match entire molecules, local methods identify smaller
fragments and try to match them individually. This raises the problem of com-
binatorics, as many local-to-local combinations have to be examined, making the
local approach more time consuming. It is useful however, when query and target
molecule follow different binding modes, or only a portion of query molecule is
responsible for binding interactions with the receptor.
Comparative studies with docking have revealed that shape similarity methods
perform as well or even better than docking,65,81 yet given the simpler approach,
are about an order of magnitude faster.48 While described here as 3D method, it
has been demonstrated to work encompassing only 2D structures of molecules with
no significant loss in results, but strong beneficial effect on speed.82 Considering its
performance in active ligand retrieval and scaffold hopping it has been suggested
to be the best option in lead discovery stage.59
2.1.5 QSAR and data mining methods
Methods described in this section share a common trait of using conventional sta-
tistical techniques on virtual screening. They cannot work on their own though,
their usage is always preceded by some parameterisation of the molecules, i.e. cal-
culation of molecular descriptors.83–85 Over the years, the number of these has
grown almost incomprehensibly large and is way beyond the scope of this thesis, or
even a single book; only a very brief summary of those most important to virtual
screening, is therefore given here.
There is a special interest in VS towards descriptors that can be calculated
quickly and capture biological properties that are essential for a drug molecule, such
as absorption in gastrointestinal tract; distribution and metabolism in organism;
and excretion; collectively denoted as ADME. Parameters that are often used to
describe them, are water-octanol partition coefficient (logP),86–89 which is used to
model the cell permeability; and water solubility,90–92 describing the overall chances
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of drug reaching the right place. The acid dissociation constant (pKa),93,94 has
also received a lot of attention. It is necessary to describe the charge distribution
of the molecule and serves therefore as the basis for calculating, for example the
distribution coefficient (logD) or tautomerisation states. When it comes to speed of
calculation, simpler is obviously better, and 1D fragment-based descriptors, such
as number of acceptor or donor sites, or number of rotatable bonds, have been
used extensively.95–97 Topological and other 2D information-based descriptors have
become common in VS.85 They are simple to calculate, and have also been proven
to be a reasonable replacement for logP.98
It should be emphasised, that the data mining techniques themselves have no
problem making use of any kind of molecular descriptors. Once they are calculated,
what follows is the application of common statistical methods, that are applica-
ble in any discipline to clusterise, classify or rank molecules. These methods are
vastly numerous and have been reviewed in context of virtual screening repeat-
edly.99–101 One of the most popular appears to be regression analysis, which in
VS, and chemoinformatics in general, is known as quantitative structure-activity
relationships (QSAR) or quantitative structure-property analysis. These methods
attempt to establish a relationship between dependent, and one or more inde-
pendent variables through statistical techniques such as multiple linear regression
(MLR), partial least squares (or projection to latent structures) (PLS), principal
component regression (PCR) or artificial neural networks (ANN). Statistical mod-
els resulting from the data mining methods allow to analyse the data set, and a
good understanding of the data allows to predict properties or activities of new
compounds. Regression analysis is generally a simple and reliable method, but it
requires the user to have a good understanding about the property or mechanism,
and the proper validation of the results. Misconceptions about this principle have
lead to publication of many inadequate models, those resulting from chance corre-
lations and containing meaningless variables;102,103 and this has had an effect on
the credibility of the whole research area.104,105 The problem has been phrased as
“Kubinyi paradox – the models that fit the best retrospectively tend to predict the
worst prospectively”.106 This has resulted in adopting more stringent development
and validation methods.107–110
When the existing data does not allow to create a strict regression model, or
it is not required, classification can be used instead, a common case in VS being
separation of active ligands from the inactive ones. A well-established method in VS
is, for example, a decision tree, where classification occurs in a successive evaluation
of descriptors, often depicted in a tree-like manner, where each leaf node denotes
a different class. They are fast and efficient to calculate,111 but have a common
problem of overtraining - it is possible to perfectly classify a training set, but in the
process, the capability of generalisation is lost i.e. the method just learns the data.
Another popular classification technique is principal component analysis (PCA).112
In this method, the information in descriptor pool is transformed into principal
components, linear combinations of input descriptors. Since principal components
are extracted in such way to maximise the information content of the descriptor,
just a handful of them are needed to capture almost all the information in descriptor
pool. It is used therefore for one, as a data reduction method. Clustering is
performed using a first few principal components, since they capture the most of
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the information contained in descriptors.
Classification can also be done by using the support vector machines (SVM).113
In this method, a hyperplane is constructed in descriptor space maximising the
distance to the nearest training data points belonging to different classes (active
and inactive for example). In its original form, SVM is a linear binary classifier,
but being an attractive method, several modifications have been proposed, which
allow the method to overcome its original limitations, and enable its usage as a
multi-class classifier,114 non-linear modeller,115 or regression method.116
A family of methods stemming from probability theory have become increas-
ingly popular in VS and chemistry in general. They are based on Bayes theorem117
and therefore referred to as Bayesian methods.118,119 In VS, they are generally used
for classification,120,121 such as in naïve Bayesian classifiers122–125 or binary ker-
nel discrimination,126,127 but in principle, they can also be used for ranking and
regression.
2.1.6 Filters
The underlying mechanisms of filter methods do not represent any conceptually new
technologies. Their purpose is, however, slightly different from other VS methods,
which is why they receive a separate section in this overview. The best known
among them is Lipinski’s rule-of-five. In 1997 Lipinski et al. studied a set of
known drugs and noticed that they tend to lie between certain values of some
simple physicochemical parameters.128 This enabled them to formulate a set of
rules, which state that the compound is likely to have poor absorption if at least
two of the four parameters are true: the number of hydrogen bond acceptors >
10, the number of hydrogen bond donors > 5, logP > 5 and molecular weight
> 500. This rather crude effort was immediately picked up by other authors129
and further enhanced by adding other parameters. Among the most popular ones
were the number of rotatable bonds, to account for molecule’s flexibility, and polar
surface area to better describe hydrogen bonding properties.130 But it did not stop
there, many other parameters were tried, such as molar refractivity, net charge,
number of heavy atoms and many others.96,97,130–133 Sets of toxic and reactive
fragments have been composed,134–136 allowing a molecule containing any of these
to be removed. Statistical models predicting ADME properties,137–139 toxicity140
and brain-blood barrier141–143 have been developed and used, as well as solubility
in water90–92 and of course endless takes on logP.86–89,144
It appears that filters exploit the concepts of “drug-likeness”,130,132,133 or “lead-
likeness”133,145,146 and attempt to focus the database to more prospective molecules
by eliminating molecules that are too large, poorly soluble, overly toxic or otherwise
unsuitable. It makes sense not to waste time on them,147 but in the light of lead
optimisation, the technique of improving quality of a hit molecule found in (virtual)
screening, there is another, more pragmatic reason. Given the size of molecular
databases, containing millions of entities, it is often desirable to restrict the initial
size of the library as early, as strongly, and with as little effort as possible. Filters
provide an intuitive and easily understandable means of achieving that. This helps
to define their scope in virtual screening. They are not specific to a single target,
they are mainly concerned with pharmacokinetic, rather than pharmacodynamic
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properties, and they are aimed to be fast, which as a result makes them quite crude,
a point succinctly illustrated by the name of one of the programs used for filtering:
REOS, or Rapid Elimination Of Swill.134
Today, filters have become common and their usage in VS is widely accepted,
thus they do not receive a lot of attention in the papers any more. It is not even
necessary to apply them, because virtual screening databases, such as ZINC38,
offer pre-filtered sets of drug-like148 or lead-like149 molecules; PubChem150 offers
filtering search results according to rule-of-five; and ChEMBL provides info about
compounds regarding rule-of-five and rule-of-three.
2.2 Comparing virtual screening methods
The number of current virtual screening methods raises a question how make a
choice between them. Comparison of methods and evaluation of their advantages,
drawbacks, performance, cost and results is therefore of highest interest. The obvi-
ous way to compare methods is based on their ability to separate active compounds
from inactive ones by classification or ranking. Several common statistical methods
can be used, such as analysis of variance (ANOVA),151 the Z-score152 or Matthews
correlation coefficient153 among others.154 Surpassing these by popularity is en-
richment factor (EF),23,155 which is calculated as in eq. 1. HITS is the number of
known actives and N is the number of compounds. The sampled  set commonly
refers to 1% or 5% of the best scoring compounds.
EF =
HITSsampled set/Nsampled set
HITStotal database/Ntotal database
(1)
To write it out in human-readable form, EF simply shows how much more
actives are contained in a set of selected N compounds compared to randomly
chosen N compounds. Completely random selection will give EF = 1; values
above that indicate concentrating the set in terms of active ligands, values below
1 mean worse than random selection.
Another frequently used method in virtual screening are the receiver-operator
characteristic (ROC) curves.156,157 They are in essence a 2D representation of
cost-benefit analysis; in virtual screening terms it says how many false positives
(compounds falsely predicted to be active) accompany true positives in a given
classifier settings. They provide a powerful and thorough insight into the method’s
performance, but being in graphical representation, are somewhat cumbersome
to compare. To yield a more comfortable, single scalar value, area under the
ROC-curve (AUC) is often used, which is equivalent to the probability that the
classifier will rank a randomly chosen positive instance higher than a randomly
chosen negative instance.157
While EF and AUC are both popular methods of assessing success of virtual
screening, they both have the ’early recognition’ problem. What it means, is that
in practical matter, VS is expected to preselect compounds form database for
experimental testing, and the successful method is expected to significantly reduce
the amount of experiments. This sets a requirement to a VS method, to rank
active compounds the best. But EF doesn’t rank compounds within threshold
limit, and AUC can evaluate curve with more suitable shape the same as worse
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one. This can be overcome by using logarithmic transformation on the curve158 or
using exponential weighting scheme.154,159 Indices have been developed to tackle
this problem, for example robust initial enhancement (RIE)159 and Boltzmann-
enhanced discrimination of receiver operating characteristic (BEDROC).154
Since the current level of virtual screening cannot guarantee to find all possible
active compounds, it is therefore of highest interest, that the set of compounds se-
lected, also contains novel chemotypes. These are structures with new scaffolds that
can explore wider areas in chemical space and are not covered by existing patents.
This so-called “scaffold hopping” ability is another criteria determining the suc-
cess of virtual screening. It is generally assumed that on this area, structure-based
methods have the advantage over ligand-based ones, because they do not set any
requirements on ligand’s structure, but only its function. That belief is not without
a reason, a recent comprehensive study by Ripphausen et al. demonstrated, that
novel chemotypes were more frequently discovered using SBVS.6 However, LBVS
had a surprising advantage: while SBVS was more successful in scaffold hopping,
LBVS often found ligands with higher experimental activity.6 Ligand-based meth-
ods rely on the concept of molecular similarity and assume the presence of known
active, and preferably also inactive ligands. The level of the performance of the
method is therefore inherently connected to the limited amount of information
provided by training compounds, and how well they sample the chemical space,
especially around activity cliffs, areas in chemical space, where small changes in
structure are accompanied by large changes in activity.160,161 LBVS methods can
be therefore likened to local models. The binding site structure, on the other hand,
contributes much more information to the process, it defines the shape of the lig-
and, as well as how it interacts with the target protein, but does it without setting
rules on how exactly atoms in the molecule should be arranged, keeping open the
possibility of fitting it with a new ligand, which looks completely different, but
has similar activity. It defines the complete possible chemical space for a potential
ligand and can therefore be seen as a global model. This is where the difference
emerges: while global models have the capacity to describe the wider area, they are
less accurate on separate entities, and that’s where local models with their closer
focus have an edge.
For purely practical reasons, method’s resource requirement is also a point
of interest, especially in the case when comparing methods with otherwise simi-
lar capacity. It can be generally said, that ligand-based methods are faster than
structure-based methods, because they have to process less information. The same
holds true also along the other important divide in VS methods, 3D methods with
their need to generate spatial geometry or to perform a conformational search, tend
to be more time-consuming than 2D methods. But when it comes to comparing
results, things are not so clear. Intuitively, putting more information into an equa-
tion should give more accurate results, but 3D methods are not significantly better
than 2D methods, and similarly, using the receptor structure doesn’t guarantee an
advantage over ligand-based methods.
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2.3 Current trends and problems in virtual screening
Virtual screening has been around now for a few decades. It has been widely
accepted as a useful technique in drug design, but despite the popularity and
active development, it has some critical problems, casting a shadow to the whole
area. This section summarises the most acute difficulties of the VS, as well as the
directions it is evolving.
Starting with the problems, this section can pick up where the last one left
off, because validation or evaluation of methods is one of the biggest concerns of
VS today. Given the number of methods in existence, it is unrealistic to compare
them all in a single study, the lack of universal standards, however, makes the
comparison across different articles precarious. While there are popular evaluation
methods, that can often be found, such as enrichment factor and ROC-curves, the
outcome depends also on which target and data sets are used. Different nature of
binding sites ensures that methods do not to work equally well on all targets, and
data sets are prone to bias, thereby favouring different methods. The reasons why
data sets are biased are purely pragmatic – when a suitable scaffold is discovered,
it is usually put through a lead modification process, meaning that a series of
compounds with the same scaffold but different substituents, are synthesized and
tested. As a result, the number of known ligands could seem large enough, but
the underlying chemical space is poorly sampled and does not provide enough
information for virtual screening158 The popular validation database, DUD, was
therefore cleaned from structural redundancy, which has in many cases significantly
reduced the individual ligand and decoy sets.40
Another critical problem, also suggested in previous section, stems from the
observation that complex and advanced methods are not always better than sim-
ple ones. An interesting study by Bender and Glen,161 where several types of
fingerprints were compared, demonstrated that a simple atom count vectors out-
performed in some cases much more sophisticated fingerprints. This is truly re-
markable, because atom count vectors are essentially molecular formula, 1D de-
scriptor, which is not really able to distinguish molecules due to high redundancy.
This raises some disturbing questions as what do we exactly know about virtual
screening. Unpredictable compound retrieval and level of accuracy when using
different methods with varying complexity, clearly indicates our poor apprehen-
sion of molecular descriptors and their interpretation.162 Despite the work done
in this area,163 the results of virtual screening are still inconsistent. An obvious
and rather crude solution at the moment would be to simply use several methods
simultaneously, and select compounds based on consensus or average.51,162,164,165
This may have a hindering effect, when one method is significantly worse than
the other, but usually covering different methods and thereby different chemical
descriptions allows to reduce false positives and negatives.
So far in the present thesis, virtual screening has been depicted as a method
to find ligands for a single target. However, VS is more versatile than that and it
is a growing trend to employ many targets in a single project. The exact opposite
of the usual paradigm is called “target fishing” and as the name suggests, it is
finding a suitable target for a known ligand.166–168 The idea of this approach is
drug re-purposing169 – existing drugs may have undiscovered beneficial effects and
since they have already undergone medicinal testing and approval, the process of
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bringing them to market becomes significantly faster and cheaper. But this is not
the only reason to use many targets. When a drug is introduced into the organism,
it has a theoretical possibility to interact with many other proteins or nucleic acids,
which may cause severe side effects. For example, the Ether-à-go-go Related Gene
(hERG),170 blocking of which is related to cardiac arrhythmia; the cytochrome
P450 superfamily,171 that play crucial roles in the metabolism and biosynthesis of
endogenous compounds, and the metabolism of drugs and non-drug xenobiotics;
pregnane X receptor (PXR),172 mediator of expression of several proteins, including
the P450 enzymes; and transporter proteins,173,174 among others.175 Identifying
these ’off-targets’ or ’anti-targets’, and testing whether they have significant affinity
towards the ligand by using virtual screening, has therefore great potential to reduce
drug candidate fail-rate in clinical trials.
Besides the targets that the drugs are not supposed to hit, there may also be
more than one target the drug is required to interact with, in order to work effec-
tively. This approach, called polypharmacology or network pharmacology,176,177
comes from the observation that designing a perfectly selective ligand for a tar-
get may not be enough for effective treatment of a disease.178 The reasons lie in
cell biology – a hugely complex structure a cell is, there is functional redundancy,
meaning that like network connection, there is a possibility to find alternative
routes to bypass the deletion of individual nodes.179–181 That means disabling one
of two genes has no significant effect on cell’s viability, but simultaneous inhibition
leads to impaired functionality or death.182–185 For example, it has been demon-
strated that synergistic effect of compound targeting two kinases is greater than
the additive sum of it acting on each kinase individually.186 Four targets have
been identified to be necessary to inhibit to stop metastatic progression of breast
cancer in mouse model.187,188 Effective antibiotics often target several rather than
single proteins,189,190 and similar observations have been made also about central
nervous system disorder drugs.191
For drug discovery, the obvious implications are, that instead of searching for
a single “disease-causing” protein, polypharmacology suggests targeting the appro-
priate subgraph in the network.192,193 In virtual screening, this can either mean
parallel screens for different protein structures using docking or pharmacophore
models, or fragment based approaches based on selected fragments known to bind
several required targets separately.194,195
As a rather fresh approach in VS, multi-target screening has, as of yet, been used
sparsely, and only a few examples can be brought here. Huang et al., in a search
of a cure for Alzheimer’s disease, used first a pharmacophore model of ￿-secretase
1 (BACE 1) inhibitors, and then filtered the results using molecular docking to
acetylcholinesterase (AChE) structure.196 The same group also reports two multi-
target cancer studies, targeting several kinases using support vector machines and
docking;197,198 and also a study on anticoagulant activities, targeting factor Xa and
thrombin in human clotting cascade.199 Prado-Prado et al. have developed ligand-
based classification approach based QSAR models, trained on known antibacterial
drugs, active against several lines.200,201 More examples can be brought from a
simpler case, where both mutant and wild-type structures of the same target are
used. This is more common, because using multiple structures is a well known
technique in docking to model protein flexibility,202 and incorporating also mutant
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protein structures, making this effectively a multi-target approach, is just a logical
step further. In here the predominant interest has towards HIV and malaria.203
To sum up the literature overview part of this thesis, VS, its methods and
paradigms undergo an extremely active development. Originally seen as simply an
in silico analogue for high-throughput screening, it has now widened its territory
outside of its traditional habitat and has become universal tool in drug design.
Most of the papers published on the subject do not simply exploit some existing
technique, but rather complement them with something new, from additional vali-
dation scheme to entirely new method. And as it can be seen in next chapter, this
holds true also for the articles this thesis is based on.
3 Methods
Virtual screening as a process can rarely manage with just one step. In addition to
the deployment of actual screening with any of the methods described in section 2.1,
the data also needs to be prepared, analysed and validated. Several methods can
be used, for example a fast filter method before the more demanding one. Virtual
screening workflows as found in literature, can therefore grow to be rather elaborate.
This chapter takes a closer look on the schemes used in individual articles this
thesis is based on. Examples of the two important paradigms in virtual screening
– SBVS and LBVS can both be found. Articles I and II employ the ligand-based
approach by following the classical QSAR methodology. A series of known ligands
is analysed with linear regression and as a result, a model is developed. Article
III uses docking as its main method, and a new structure-based VS method is
developed in the fourth one.
3.1 QSAR and data mining
Articles I and II use a similar set of methods which are described in section 2.1.5.
In both cases, a multiple linear regression model is developed on a set of training
compounds with a goal of analysing the existing data and predicting properties of
new molecules.
The first step in the workflow was the conformational search with Macro-
Model,204 followed by geometry optimisations and quantum-chemical calcula-
tions with MOPAC,205 and calculation of several topological, geometric, charge
distibution-related and quantum-chemical molecular descriptors with CODESSA
software.206,207 After calculation, descriptors were subjected to nonlinear trans-
formations, namely inverse, square, square-root and logarithmic. This is due to
the observation, that the relationship between property and parameters is often
nonlinear, therefore these transformations help to fit the property more accurately.
Prior to the model development, an additional clustering step was used in article
II, where the data set was broken down into smaller pieces and individual QSAR
models were derived on these subsets. Cluster analysis was performed with the
PCA methodology and the classification was done based on score plot of first two
principal components, which were found to be correlated to size and hydrophobicity.
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Descriptor selection and model development was carried out using CODESSA’s
Best Multi-Linear Regression (BMLR) method,207 which is essentially a forward
selection method, where descriptors are successively added to existing models, and
retained if significant improvement in statistics is observed. All models were val-
idated internally using statistical tests – cross-validated correlation coefficients,
F-test and t-test; external validation using a set of test compounds was carried out
where possible.
When used in virtual screening, the applicability domain of the models must be
considered. As a similarity-based method, the models do not perform reliably on
compounds significantly different form those in training set, therefore it would not
make sense to apply it on entire ZINC library for example. Instead, a combinatorial
library can be created, using a set of possible substituents (analysis of outliers in
the papers can be helpful at this point) and adding them to the proper locations
in core structure.
3.2 Docking
Molecular docking was used as the predominant method in article III, and as an
additional validation method in article IV. Due to problems with exact activity
prediction and ranking, as pointed out in section 2.1.1, a common practice is to
compare the results with known good, and if possible, bad binders. The score
values of good binders, such as existing drugs or other known ligands, are used to
set the threshold value for new ligands. If some known bad binders are available,
they can be used to make sure, that the algorithm can tell them apart from good
ligands. This approach was also used in article IV.
Article III however, employs a much more comprehensive and stringent selection
process. The schematic depiction of the workflow is brought in figure 1. Ligands
were chosen from the ZINC database, which at first was filtered to manageable size
using a set of pharmacokinetic and structural rules. The filter parameters were set
based on literature96,97,128,130,131,208 and are depicted in table 1. The approach
used was conservative, while rule-of-five allows some rules to be broken, this time
all compounds had to comply exactly. The objective was to retain only a small
subset, so that the following docking would not take excessively long time. After
applying all filters, the initial database of 5,627,809 compounds was reduced to just
65,035.
Several X-ray structures of the receptor were used, covering wild-type and mu-
tant structures, different hydration states and some conformational flexibility. A
set of five anti-targets were used, human sulfotransferase 1A3, pregnane X receptor,
and three cytochrome P450 enzymes. They are some of the proteins that the drug
is likely to interact with in the organism, and could therefore alter it’s potency.
Two docking programs were used in the study, Autodock and Glide, to get two
opinions on ligands, but the consensus was used differently with targets and anti-
targets. With targets, to reduce the occurrence of false positives, both programs
had to give high rating to the ligand, higher than the set of known ligands used for
reference. With anti-targets, as a safety measure, high score from only one sufficed.
After docking, additional ranking was performed according to the efficiency
indices, and the number of hydrogen bonds formed with the protein backbone.
22
Min Max
Water-octanol partition coefficient logP -3 5
Molecular weight (g/mol) 300 650
Number of rotatable bonds 5 12
Topological polar surface area209 (A2) 25 180
Number of hydrogen bond acceptors 2
Number of hydrogen bond donors 3
Solubility in water logS -5
Number of rings 6
Number of fused rings 6
Ring size 7
Table 1: Filtering parameters.
Protein chain backbone atoms are less susceptible to mutations than side chain
atoms, they are often found to be more stable and easier to detect from X-ray
studies, which makes their position more reliable. Therefore, re-ranking ligands
according to hydrogen bonds with protein backbone, gives preference to ligands
that are less affected by mutations. Ligand efficiency indices are free energy of
binding normalised with molecular weight or any other available parameters, in-
cluding and not limited to molecular surface area, polar surface area, the number
of heavy atoms or the number of rotatable bonds; and can thereby indicate effec-
tive binding per atom or other pharmacokinetically relevant parameter.210,211 It
has been detected that they are able to improve correlations between experimen-
tal and calculated binding parameters211 and separate drugs from non-drugs. In
this study, they were calculated using the average binding energy across different
programs and target structures. As a result of these additional steps, the ligands
selected are more likely to be pharmacologically relevant.
3.3 Topological docking
Topological docking is a novel structure-based virtual screening method, which
development and deployment is described in article IV. The method starts with
transforming the 3D structure of the binding site into the 2D distance matrix, in
order for it to be directly comparable with the molecular graph. Hydrophobic,
hydrogen bond donor and hydrogen bond acceptor subsites are identified and a
point in three-dimensional space is assigned to each, usually coinciding with the
centre of the area. To complete the transformation, distances between all points
are calculated and stored in a distance matrix. Distances are measured along the
shortest path that does not intersect with the protein surface that ensures more
accurate description of the binding site, because it implicitly defines forbidden areas
for the ligand.
Principally, the topological representation of the molecule is already in the form
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Figure 1: The workflow in article III.
of the distance matrix, but some small modifications are still necessary. Hydro-
gen bond donors and acceptors reside on one atom, but since hydrophobic areas
in the molecule are comprised of several atoms, they need to be described using
an additional dummy atom. Distance matrix is composed now using the donors,
acceptors and dummy atoms marking the hydrophobic centre. Distances this time
are not distances in three-dimensional space but rather along the shortest path in
the molecular graph. This approach ensures a certain amount of flexibility of both
protein and ligand to be accounted for, because distances along the path in molec-
ular graph should almost always exceed the corresponding distances in 3D space,
unless the molecular fragment is perfectly rigid and linear, an extremely rare case
when more than 3 atoms are involved.
Testing whether a ligand fits into the binding site is achieved by a process which
can be viewed as comparing the corresponding distance matrices. Two matrices,
overlaid onto each other, depict a pose of the ligand, i.e. the way the ligand’s
functional groups are assigned into the subsites in the binding pocket. This is
analogous to an actual three-dimensional arrangement of the ligand in the binding
site, as in docking, ensuring a clear interpretation of the results. When the distances
in ligand’s matrix are greater than or equal to those in binding site’s matrix, the
pose is considered a match, otherwise it is rejected and a new pose is evaluated.
Generating a new pose is as simple as shuffling the columns in one of the matrices.
Besides the pose, size of the ligand is also assessed, whether the molecule can
actually fit into the binding site, or is it too big for this. Altogether this makes the
process quite similar to docking, hence the method was called ’topological docking’.
Testing and development was done on six target systems: poly(ADP-ribose)
polymerase, P38 mitogen activated protein kinase, phosphodiesterase 5A, platelet
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derived growth factor receptor kinase, thrombin and HIV-1 protease. Data for the
tests, active ligands and non-active decoys were acquired from the DUD database,
and a subset of around 7,000 randomly selected compounds were used from the
ZINC database. A full-scale screening for HIV-1 protease inhibitors was performed
on the entire ZINC database, about 14 million compounds, and the results were
further validated with docking.
4 Summary of original publications
4.1 QSAR Modeling of HIV-1 Protease Inhibition on Six-
and Seven-membered Cyclic Ureas
Inhibiting HIV-1 protease is a potential pathway of blocking the reproduction of
virus in organism, and as such has been an object of interest in drug design since
1988212. Several known drugs are exploiting that mechanism, such as Saquinavir
or Atazanavir among others. Protease inhibitors usually form hydrogen bonds not
only directly with the protein itself but also to a water molecule in the active site
of protease. The cyclic urea-based inhibitors (figure 2, a), developed by DuPont
Merck213 are therefore an unconventional class of inhibitors because the carbonyl
atom in the core structure effectively replaces the water molecule, giving the in-
hibitors of this type higher entropic efficiency.
Article I describes the development of linear QSAR model that can predict the
activities of cyclic urea-based HIV-1 protease inhibitors. The model is based on
large and diverse data set, and according to statistical parameters fits the training
data well (R2 = 0:82; s = 0:46). The standard error of estimation was close to
experimental error of measurement found in the source articles, indicating that fur-
ther improvement begins to compromise the generalisation and lead to overfitting.
The model was validated both internally (using statistical tests) and externally
(with a set of compounds not used in model training). The model contained four pa-
rameters, one topological descriptor, describing the size and shape of the molecule;
and three charge distribution-related descriptors, which characterised the hydrogen
bonding and electrostatic properties of ligand molecules. None of the descriptors
require laborious quantum-mechanical calculations, they are all simple and fast to
calculate, making the model especially suitable for virtual screening. Some care
must be taken about conformational analysis because these types of inhibitors are
quite flexible. The analysis of the model’s applicability domain revealed that due to
the diverse training set it successfully functions over a wide range of substituents.
Problematic areas were detected around structures with rare functional groups and
also isomery.
4.2 The QSAR Modeling of Cytotoxicity on Anthraquinones
Cytotoxicity in virtual screening is often related to cancer treatment studies. Ar-
ticle II examines the case of anthraquinone derivatives (figure 2, b), and their
cytotoxicity on human hepatoma G2 cell line. Similarly to article I, the initial plan
was to compose a large and diverse data set, and develop a fairly general model to
predict anthraquinones cytotoxic activity. The problem, however, turned out to
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Figure 2: Core structures used in article I (a) and article II (b).
be more difficult, and instead of a single model, a classification scheme and three
separate models for each class was required for successful modelling.
The data set was divided into three classes based on first two principal com-
ponents of the PCA analysis, which were related to size and hydrophobicity. The
largest of these, 47 compounds, contained the most hydrophobic ones, and the pa-
rameters in the resulting model describe the molecule’s polarity, electrostatic-, and
other charge distribution-related properties. Second group contains compounds
with least hydrophobicity, most compounds which were protonated under physio-
logical condition, were placed in this group by the PCA. Descriptors in the model
are appropriate, all three describe the charge distribution. Final PCA cluster was
the smallest (20 compounds) and their characteristic properties were small size
and low hydrophobicity. Besides the size and hydrophobicity, the descriptors in
the model were also related to reactivity.
Why this data set, which was not particularly big or terribly diverse did not
yield any meaningful results on the whole and needed to be broken into smaller sets,
remains somewhat unclear. It can be speculated to be caused by the complicated
property. The toxicity of anthraquinones is attributed to their intercalation with
the DNA. Their three-ring core structure is planar, aromatic and suitably sized to
fit between the base pairs of the DNA strand, disrupting thereby it’s transcription,
replication and repair processes. Other unknown toxicity pathways, though less
likely, can also not be excluded. Additionally, the property measured was not
directly the binding to the DNA, but rather the 50% inhibition of cellular growth
(IC50), so pharmacokinetic in addition to pharmacodynamic properties (such as
solubility and membrane permeation), come into play. Since the property seemed
to contain too many unknowns, the best we could do was to provide a clustering
scheme and derive focused models for different classes which were statistically more
coherent.
4.3 Combined Approach Using Ligand Efficiency, Cross-
Docking, and Antitarget Hits for Wild-Type and Drug-
Resistant Y181C HIV-1 Reverse Transcriptase
HIV-1 reverse transcriptase (HIVRT) is an attractive target in AIDS treatment. Its
function, producing a DNA sequence from viral RNA, is unprecedented in humans,
allowing theoretically the design of highly selective inhibitors. It’s attractiveness is
however somewhat hindered by it’s fast mutation rate, which enables the virus to
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quickly develop resistance to drugs.214 Despite several drugs already in existence,
the search for new HIVRT inhibitors actively continues. This is also the aim in
article III, which is set out to find novel ligands, that are effective against both
wild type and Y181C mutant structures, a troublesome mutation which modifies
the binding site to the extent of causing drug resistance.215
This paper brings an example of how virtual screening can be used in a more
thorough manner than just finding some potential hits. A comprehensive profile
was compiled of the potential ligands, considering not only their estimated activity,
but also sensitivity to a mutation, adaptability to HIVRT’s rather flexible binding
site, and the activity against anti-targets, proteins that the drug is likely to come
across in the organism while travelling to the site of action. As a result, a number of
small and structurally diverse compounds were identified as a potential inhibitors of
both wild-type and mutant HIVRT, which having passed all the selection criteria,
are expected to have higher likelihood of surviving in the following steps of the
drug design process.
Post-screening research revealed that some of the proposed ligands also ap-
peared to be active against other targets, exhibiting anti-tumor and anti-influenza
properties. This confirms the sound composition principles of the data set used in
docking. The pharmacokinetic rules applied onto the set concentrated the database
in terms of pharmacologically relevant compounds and thus allow it to be used as
a starting point in virtual screening workflow. The versatility of this set is also
demonstrated by the fact that it has been successfully employed in other projects
besides the current article. Inhibitors have been found for E3 ubiquitin ligase
neuregulin receptor degrading protein 1 (Nrdp1), Ras-related C3 botulinum toxin
substrate 1 (Rac1) (both currently unpublished), and avian influenza H5N1 neu-
raminidase.216
4.4 A Novel Structure-based Virtual Screening Method
Finds Active Ligands through the Process of ’Topologi-
cal Docking’
The fourth article describes the development of a new virtual screening method,
which attempts to combine the generalisation power of structure-based methods
with the ease of computation allowed by encompassing only 2D information of
the ligand molecules. Previous work on environmental toxicology,98 had revealed
that the topological representation is a thorough and powerful way to describe a
molecule, especially in the case of a drug-like molecules, which are preferably quite
rigid and limited in size. For that reason, abandoning 3D information does not
result in a critical loss of information, but gains an advantage in speed, therefore
the method aims to be a quick and accurate scanning method for large databases.
The main result of the article, the method itself, is described in section 3.3, so
just a few points are left to emphasise here. As it is common in VS, the method’s
behaviour was different on different targets. The results ranged from unsuccessful
in the case of poly(ADP-ribose) polymerase, where the method was unable to
discriminate active ligands from decoys, to great in the case of HIV protease, where
almost 1,000-fold reduction of the input data was observed. Subsequent docking
of HIV protease results found several ligands with known experimental activity,
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confirming method’s capability to recognise active ligands.
The analysis of these results revealed, that the current problem areas are mainly
concentrated around binding site description, especially small and hydrophobic
binding pockets. Currently the method appears to be too coarse and has too low
resolution to achieve sufficiently detailed description of such binding sites. This is
the reason behind the good results on the HIV protease, its binding site is large
and well-defined, giving the reason to believe, that the method can be improved
with more sophisticated handling of the binding sites.
5 Summary
Virtual screening is currently under great interest and active development, thanks
to its potential to significantly reduce the time and cost of the drug development
process. It is a vast and prospective research area, comprising of several paradigms
and numerous individual methods. The present thesis takes a closer look on some of
them, as an example of ligand-based methods, a classical QSAR approach is tried,
and from structure-based methods, docking was the primary choice. As a result of
this work, QSAR models describing the activity of cyclic urea-based HIV-1 protease
inhibitors and anthraquinone-based cytotoxic compounds were found; a focused
library of drug-like molecules for virtual screening was composed; a few prospective
ligands for HIV-1 protease and HIV-1 reverse transcriptase were discovered; and
as a summarisation of the accumulated knowledge over the PhD studies, a new
virtual screening method was developed.
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Summary in Estonian
Sobiva omaduste profiiliga ühendite tuvastamine keemiliste struktuuride
andmekogudest
Keemiliste ühendite digitaalsete andmebaaside kasutuselevõtuga kaasneb vajadus
leida neist arvutuslikke vahendeid kasutades sobivate omadustega molekule. Prob-
leem on eriti huvipakkuv ravimitööstuses, kus aja- ja ressursimahukate katsete
asendamine arvutustega, võimaldab märkimisväärset säästu. Ravimitele esitata-
vate rangete ohutusnõuete tõttu ei ole lähemas tulevikus kindlasti võimalik kogu
ravimidisaini protsessi algusest lõpuni arvutitesse ümber kolida. Isegi täpseimad
kasutada olevad meetodid ei suuda järjekindla usaldusväärsusega ennustada kui-
das käituks mingi aine ravimina, kas ta on sobival määral efektiivne, kas tal on
mürgiseid või muidu põnevaid kõrvaltoimeid, ning palju muud potentsiaalsele pat-
siendile huvipakkuvat informatsiooni. Kuid lugu on teine, kui vaadelda suuri and-
mekogusid. Arvutusmeetod, mis töötab teadaoleva statistilise vea piires, visates
välja mõne sobiva ühendi ja lugedes mõni ekslikult aktiivseks, tihendab lõppkok-
kuvõttes andmekomplekti tuntaval määral huvitavate ühendite suhtes. Seetõttu on
ravimiarenduse lihtsamate ja vähenõudlikkumade etappide puhul, nagu juhtühen-
dite või ravimikandidaatide leidmine, edukalt võimalik rakendada arvutuslikke va-
hendeid.
Selline tegevus on tuntud virtuaalsõelumisena ning seda ongi käesolevas dokto-
ritöös uuritud. Ülevaate temaatikast võib leida töö sissejuhatavast osast peatükist
2, kokkuvõtte töö aluseks olevates artiklites kasutatud metoodikast ning tulemus-
test vastavalt peatükkidest 3 ja 4. Töö põhineb neljal artiklil, millest kahes esimeses
kasutatakse ligandipõhist lähenemist s.t. kasutades ainult teadmisi senituntud li-
gandidest, püütakse leida ühendeid, mis on neile struktuurilt sarnased ning võiks
eeldatavasti olla seda ka aktiivsuselt. Mõlemal juhtumil koostatakse teadaoleva-
te aktiivsustega ühendite andmekomplekti põhjal lineaarne regressioonimudel, mis
võimaldab ennustada uute samalaadsete ühendite aktiivsusi. Artiklis I on uuri-
misobjektiks HIV-1 proteaasi tsüklilisel uureal põhinevad inhibiitorid. Tulemusena
leitakse lihtne ning kiirelt arvutatavate parameetritega mudel, mis on vägagi sobiv
suuremahuliseks sõelumiseks. Molekulaardsekriptorid mudelis kirjeldavad moleku-
li suurust ja kuju, elektrostaatilisi omadusi, ning vesiniksideme andmise võimet.
Artiklis II analüüsitakse antrakinoonide tsütotoksilisust. Keerulisema andmesti-
ku tõttu jagatakse ühendid eelnevalt struktuurselt erinevatesse klassidesse, seejä-
rel sarnaselt esimese artikliga lineaarset regressiooni kasutades leitakse mudelid
kirjeldamaks erinevatesse klassidesse kuuluvate ühendite tsütotoksilisust. Mudeli-
tes leiavad kajastust erinevad suurust, hüdrofoobsust ja laengujaotust kirjeldavad
deskriptorid. Nii uureate kui antrakinoonide puhul on deskriptorite valik bioloo-
gilise mehhanismi kontekstis põhjendatud, ning mudelid on sisemiselt, võimaluse
korral ka väliselt, valideeritud.
Artiklis III kasutatakse retseptoripõhist lähenemist. Sel puhul on vajalik teada
retseptori, kuhu ligand toimet avaldab, kolmemõõtmelist struktuuri. Antud töös on
selleks HIV-1 pöördtranskriptaas, ning tulemusena leitakse ligandid, mis hinnan-
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guliselt on aktiivsed nii loodusliku kui ka muteerunud pöördtranskriptaasi vastu,
kuid samas ei toimi mõningate teiste oluliste organismis leiduvate ensüümide vastu.
Töö tulemuste hulgas on ka eeltöödeldud andmekomplekt, mis sisaldab suurema
tõenäousega juhtühendiks või ravimikandidaadiks sobivaid molekule kui juhuslik
valik, ning mis on end juba mitmes töös heast küljest näidanud.
Viimases artiklis kirjeldatakse uut retseptoripõhist sõelumismeetodit, mis sar-
naneb veidi dokkimisele kuna piltlikult sobitab ligandi retseptori aktiivtsentrisse,
kuid erinevalt dokkimisest ei vaja ühendite kolmemõõtmelisi geomeetriaid, vaid
piirdub molekuli graafiga. Kahemõõtmelise molekuli kujutusviisiga piirdumine ei
kaota ühendi kohta kuigi palju infot, kuna ravimitena huvipakkuvad ühendid on
piiratud suurusega ning suhteliselt jäigad, kuid annab eeliseks suurema töökiiruse.
Kõrvaltulemuseks on meetodi valideerimise käigus leitud potentsiaalselt aktiivsed
ligandid HIV-1 proteaasile.
Virtuaalsõelumine on avar ning praegusel hetkel hoogsalt arenev uurimisteema,
mille lai haare teeb selle käsitlemise ühe töö mahus keeruliseks. Käesolevas dokto-
ritöös on tehtud valik mõningate suundade kasuks, ning uuritud nende võimekust
ja tulemuslikkust erinevate projektide raames. Töö tulemusena on valminud mõ-
ned kasutusvalmis mudelid, eeltöödeldud andmekomplekt – mugav lähtepositsioon
edasisteks töödeks; ning omandatud teadmistepagas virtuaalsõelumise vallas on
leidnud väljundi uue meetodi väljatöötamises.
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